Tiger Brokers

  • Quotes
  • Invest
  • Pricing
  • Rewards
  • Support
  • TigerAI
  • Learn
  • About
  • LOGIN
  • SIGN UP
HK StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

KEYMED BIO-B

62.050
+1.9503.24%
Volume:1.36M
Turnover:84.03M
Market Cap:18.55B
PE:-28.83
High:63.000
Open:60.000
Low:59.650
Close:60.100
Loading ...
OverviewCompanyNewsFilings

KeyMed Biosciences FY Revenue RMB 36 Million

THOMSON REUTERS
·
24 Mar

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS
·
08 Feb

KeyMed Biosciences Announces Approval of Stapokibart for the Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS
·
08 Feb

Keymed Biosciences Get China Nod for Supplementary NDA of Rhinitis Drug

MT Newswires Live
·
07 Feb

KeyMed Biosciences - Nmpa Approved Snda of Stapokibart for Treatment of Seasonal Allergic Rhinitis

THOMSON REUTERS
·
07 Feb

Analyst Rate

Buy
Buy
100.00%
Hold
0.00%
Sell
0.00%

Corporate Actions

Financial Report Announcement
Mar 24, 2025 Post Market
Financial Report Announcement
Aug 27, 2024 Post Market
Financial Report Announcement
Mar 26, 2024
Financial Report Announcement
Aug 24, 2023
Financial Report Announcement
Mar 17, 2023

Dividend History

no data

No relevant data is available

Valuation Analysis

-31.41
Current
-25.12
Sector Average
36.58%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-31.41
Maximum
-0.98
+1 STD
-5.87
Minimum
-73.56
-1 STD
-44.37
Average
-25.12

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Fintech (Singapore) Pte. Ltd.
Email Address:
uservice@ttm.financial
User Agreement|Privacy Policy

Copyright © Tiger Fintech (Singapore) Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.